MedTrace Logo

Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure

NCT00318812 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2016-05-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if oral Heme Iron Polypeptide is as effective as intravenous (IV) iron sucrose in the treatment of iron-deficiency anemia for patients with chronic kidney disease.

Conditions

Interventions

DRUG

Heme Iron Polypeptide (Proferrin)

Heme iron polypeptide 11mg po tid for 6 months

DRUG

Iron sucrose (Venofer)

Iron sucrose infusion IV q month x 6 months

Sponsors & Collaborators

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Deborah Zimmerman, MD · Ottawa Hospital Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00318812 on ClinicalTrials.gov